Loading...
XNAS
PRQR
Market cap220mUSD
Dec 05, Last price  
2.09USD
1D
-1.42%
1Q
-14.69%
Jan 2017
-57.35%
IPO
-87.23%
Name

ProQR Therapeutics NV

Chart & Performance

D1W1MN
XNAS:PRQR chart
P/E
—
P/S
10.00
EPS
—
Div Yield, %
—
Shrs. gr., 5y
14.76%
Rev. gr., 5y
57.79%
Revenues
19m
+190.22%
0313,0009,407,0002,282,000-1,529,0004,941,0001,933,00001,354,0004,037,0006,514,00018,905,000
Net income
-28m
L-1.27%
-3,253,000-12,127,000-20,832,000-39,103,000-43,637,000-36,894,000-56,746,000-46,614,000-61,680,000-64,891,000-28,119,000-27,763,000
CFO
-36m
L
-2,332,000-14,457,000-24,232,000-34,221,000-34,951,000-30,682,000-43,970,000-47,060,000-26,012,000-68,508,00021,548,000-36,393,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
URL
https://www.proqr.com/
IPO date
Sep 18, 2014
Employees
130
Domiciled in
NL
Incorporated in
NL

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT